Market Cap (In USD)
3.49 Million
Revenue (In USD)
-
Net Income (In USD)
-5 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.008-0.0087
- PE
- -
- EPS
- -
- Beta Value
- 0.25
- ISIN
- US74365N1110
- CUSIP
- 74365N111
- CIK
- 1022899
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Garo H. Armen Ph.D.
- Employee Count
- -
- Website
- http://www.protagenic.com
- Ipo Date
- 2021-04-27
- Details
- Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
More Stocks
-
PARAS
-
VRFILMSV R FILMS & STUDIOS LIMITED
VRFILMS
-
BAINFBASE, Inc.
BAINF
-
2588BOC Aviation Limited
2588
-
EDXCEndexx Corporation
EDXC
-
002778
-
GWH-WTESS Tech, Inc. WT
GWH-WT
-
OLGPFOlam Group Limited
OLGPF